

THOMSON  DELPHION		RESEARCH Home New Files Search Scores Contact Us Products	PRODUCTS Search Help Number Format Advanced Database	INSIDE DELPHION Home New Files Search Scores Contact Us Products
--	--	---	--	--

The Delphion Integrated View

Buy Now:  PDF | [More choices...](#)

Tools: [Citation Link](#) | Add to Work File: [Create new Work](#)

View: [Expand Details](#) | [INPADOC](#) | Jump to:  Go to: [Derwent](#)

 [Email](#)


🔍 Title: **US6063759: Conjugate of biologically active compound and polar lip conjugated to a microparticle for biological targeting**

[[Derwent Title](#)]

🌐 Country: **US** United States of America

👤 Inventor: **Yatvin, Milton B.**; Portland, OR
Stowell, Michael H B; Fulbourn, United Kingdom
Gallicchio, Vincent S.; Lexington, KY
Meredith, Michael J.; Lake Oswego, OR

👤 Assignee: **Oregon Health Sciences University**, Portland, OR
 other patents from [OREGON HEALTH SCIENCES UNIVERSITY](#)
[\(420630\)](#) (approx. 161)
[News, Profiles, Stocks and More about this company](#)



📅 Published / Filed: **2000-05-16** / 1998-04-14

📄 Application Number: **US1998000060011**

🔍 IPC Code: **A01N 37/18**; **A61K 9/127**; **A61K 47/00**; **C12N 5/08**; **C07K 17/00**;

📄 ECLA Code: **C07H19/06E**; **C07H19/10E**;

🇺🇸 U.S. Class: **514/002**; **424/450**; **435/176**; **435/178**; **435/179**; **435/180**; **435/325**;
435/366; **530/300**; **530/329**; **530/331**; **530/811**; **530/813**; **530/814**;
530/815;

🔍 Field of Search: **514/002 424/450 536/051,78,28.2 436/518,528**
530/300,331,329,810,815,811,813,814
435/174,180,325,366,176,178,179

🏛 Government Interest: This invention was made with government support under grant 1-R01-CA49416 by the National Institutes of Health. The government has certain rights in the invention.

📅 Priority Number: 1998-04-14 **US1998000060011**
 1996-08-01 **US1996000691891**
 1995-05-16 **US1995000441770**
 1994-05-19 **US1994000246941**
 1993-10-26 **US1993000142771**
 1992-07-09 **US1992000911209**
 1990-11-01 **US1990000607982**

📄 Abstract: Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a

microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

⚡ Attorney, Agent or Firm: **McDonnell Boehnen Hulbert & Berghoff ;**

⚡ Primary / Assistant Examiner: **Naff, David M.;**

⚡ INPADOC

None

Buy Now: [Family Legal Status Report](#)

Legal Status:

⚡ Related Applications:

Go to Result Set: 1 patent(s) that list this one as related

Application Number	Filed	Patent	Pub. Date	Title
US1996000691891	1996-08-01	US5840674	1998-11-24	Covalent microparticle-drug conjugates for biological ta
US1995000441770	1995-05-16	US5543391	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1994000246941	1994-05-19	US5543390	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1993000142771	1993-10-26	US5543389	1996-08-06	Covalent polar lipid-peptide conjugates for use in salve
US1992000911209	1992-07-09	US5256641	1993-10-26	Covalent polar lipid-peptide conjugates for immunologic targeting
US1990000607982	1990-11-01	US5149794	1992-09-22	Covalent lipid-drug conjugate drug targeting

⚡ Parent Case:

This application is a continuation of application Ser. No. 08/691,891, filed Aug. 1, 1996, now U.S. Pat. No. [5,840,674](#), which is a continuation of application Ser. No. 08/441,770, filed May 16, 1995, now U.S. Pat. No. [5,543,391](#), which is a continuation of application Ser. No. 08/246,941, filed May 19, 1994, now U.S. Pat. No. [5,543,390](#), which is a continuation-in-part of application Ser. No. 08/142,771, filed Oct. 26, 1993, now U.S. Pat. No. [5,543,389](#), which is a continuation-in-part of application Ser. No. 07/911,209, filed Jul. 9, 1992, now U.S. Pat. No. [5,256,641](#), which is a continuation-in-part of application Ser. No. 07/607,982, filed Nov. 1, 1990, now U.S. Pat. No. [5,149,794](#), the disclosures of each of which are herein incorporated by reference in its entirety.

⚡ Designated Country:

AM AP BB BG BR BY CA CN CZ EE FI GE HU IS KE KG KP KR KZ LK LR LT LV BE
FR GB GR IE IT LI LU MC

Family: [Show 24 known family members](#)

First Claim: [Show all 69 claims](#)

What is claimed is:

1. A composition of matter comprising a prodrug of a biologically-active compound, a microparticle and a cleavable linker moiety comprising two linker functional groups, wherein the cleavable linker moiety has a first end and a second end and wherein the microparticle is attached to the first end of the linker moiety through a first linker functional group and the prodrug attached to the second end of the linker moiety through a second linker functional group, and wherein the cleavable linker moiety is non-specifically cleaved inside a phagocytic mammalian cell, and wherein the prodrug comprises a biologically active compound, a polar lipid moiety comprised of one or a plurality of polar lipid molecules and a specific linker moiety, wherein the specific linker moiety is covalently linked to both the biologically active compound and the polar lipid moiety, wherein the specific linker moiety is specifically cleaved in a phagocytic mammalian cell infected with a microorganism and is specifically activated thereby.

Background / Summary: [Show background / summary](#)

Drawing: [Show drawing descriptions](#)

Descriptions:





Description: [Show description](#)

Forward: [Show 2 U.S. patent\(s\) that reference this one](#)








References:













U.S. References: [Go to Result Set: All U.S. references](#) | [Forward references \(2\)](#) | [Backward references](#)
[Citation Link](#)



Buy PDF	Patent	Pub.Date	Inventor	Assignee	Title
	US4780455	1988-10	Liberman et al.	The Trustees of Columbia University in the City of New York	Lipophilic compounds for pharmacological and organic compounds
	US4793986	1988-12	Serino et al.	Johnson Matthey, Inc.	Macromolecular antitumor compounds
	US4847240	1989-07	Ryser et al.	The Trustees of Boston University	Method of effecting uptake of molecules
	US5053394	1991-10	Ellestad et al.	American Cyanamid Company	Targeted forms of methylthio agents
	US5149794	1992-09	Yatvin et al.	State of Oregon	Covalent lipid-drug conjugates for drug targeting
	US5256641	1993-10	Yatvin et al.	State of Oregon	Covalent polar peptide conjugates for immunological targeting
	US5258453	1993-11	Kopecek et al.	University of Utah	Drug delivery system for the simultaneous release of drugs activated by enzymes and ligands
				State of Oregon, Acting by and Through the Oregon State	Covalent polar

	US5543389	1996-08	Yatvin et al.	Board of Higher Education on Behalf of the Oregon Health Sciences University, a non profit organization	<u>peptide conjugates in salves</u>
	US5543390	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	<u>Covalent microparticle drug conjugates biological target</u>
	US5543391	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	<u>Covalent microparticle drug conjugates biological target</u>
	US5840674	1998-11	Yatvin et al.	Oregon Health Sciences University	<u>Covalent microparticle drug conjugates biological target</u>

Foreign References:

Buy PDF	Publication	Date	IPC Code	Assignee	Title
	EP0077529	1983-04	C07C 93/187	Sanol Schwarz GmbH	<u>Medicinal form</u>
	EP0109484	1983-04	G08B 21/00	Trampnau, Ulrich	<u>Warning device for helicopters</u>
	EP0203676	1986-12	A61K 39/12	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	<u>Vaccine for generation of immunogenic response protein against a virus</u>
	EP0279887	1988-08	C07C 101/30	Kesner, Leo	<u>Carnitine derivatives pharmaceuticals and their use for manufacture of medicament for treatment of metabolic disorder</u>
	WO8911299	1989-11	A61K 49/00	STATE OF OREGON acting by and through THE STATE ...	<u>METHOD FOR DELIVERY OF THERAPEUTIC TO TARGET BLOOD TISSUE USING MONOCLONAL ANTIBODY CONJUGATES</u>
	WO8910348	1989-11	C07C 99/10	GIBBONS, William, Anthony	<u>FATTY AMINO ACID AND HOMO- AND HETERO-OLIGOMER AND CONJUGATES THEREOF</u>
	WO9000555	1990-01	C07H 15/12	VICAL, INC.	<u>LIPID DERIVATIVES ANTIVIRAL NUCLEOSIDE LIPOSOMAL INCORPORATION METHOD OF</u>
					<u>COVALENT CONJUGATES</u>

	WO9010448	1990-09	A61K 31/70	GENENTECH, INC.	AND OLIGONUCLE
	WO9101750	1991-02	A61K 39/02	UNIVAX BIOLOGICS INCORPORATED	LIPID A ANALOG/IMM CARRIER CO AND THE USE AS VACCINES
	WO9116024	1991-10	A61F 13/00	VICAL, INC.	CATIONIC LIP INTRACELLU DELIVERY OF BIOLOGICALL MOLECULES
	WO9119726A	1991-12	C07H 17/00	KUCERA, Louis, S.	ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES
	WO9401131	1994-01	A61K 39/00	EUKARION, INC.	TRANSVASCUL INTRACELLU DELIVERY OF PROTEINS
	WO9401138	1994-01	A61K 47/48	STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION on behalf of the OREGON HEALTH SCIENCES UNIVERSITY	COVALENT P LIPID-PEPTID CONJUGATES BIOLOGICAL TARGETING
	WO9402178	1994-02	A61K 47/48	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as	TARGETING O LIPOSOMES T BLOOD-BRAIN BARRIER
	WO9403424	1994-02	C07C 323/41	DRUG DELIVERY SYSTEM INSTITUTE, LTD.	COMPOUND OF INTRACER RESIDENCE A THEREOF
	WO9406450	1994-03	A61K 37/00	UNIVERSITY OF FLORIDA	BRAIN-ENHANC DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM
	WO9425616	1994-11	C12P 21/00	WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY	CELL-TARGET PORE-FORMING AGENTS
	WO9507092	1995-03	A61K 38/00	THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY	BLOOD-BRAIN TRANSPORT OF NEUROLOGIC AGENTS
	WO9522963	1995-08	A61K 9/51	MEDINOVA MEDICAL CONSULTING GMBH	DRUG TARGETING SYSTEM, METHOD PREPARING SAME AND ITS USE
	WO9532002	1995-11	A61K 47/48	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH	COVALENT MICROPARTICLE CONJUGATES BIOLOGICAL TARGETING

				SCIENCES UNIVERSITY	
	WO9604001	1996-02	A61K 38/00	MOLECULAR/STRUCTURAL BIOTECHNOLOGIES, INC.	SITE-SPECIFIC BIOMOLECULAR COMPLEXES
	WO9622303	1996-07	C07J 5/00	BENDER, Veronika, Judith	THERAPEUTIC COMPOUND ACID CONJUGATE

Other Abstract Info: CHEMABS 118(04)027456V CHEMABS 120(24)307470P CHEMABS 124(14)185548E 125(16)204546S CHEMABS 125(18)230787R CHEMABS 129(25)335730C DERABS C 340298 DERABS C1993-350862 DERABS C1996-020359

- Other References:
- Abbas et al., "Antigen Presentation and T Cell Antigen Recognition," Cellular as J. Mo (W.B. Saunders Co.; Philadelphia), pp. 116-136.
 - Afzelius et al., Biochim. Biophys. Acta 979: 231-238 (1989).
 - Alvarez-Dominquez et al., "Role of Complement Component C1q in Phagocytosis of L monocytogenes by Murine Macrophage-Like Cell Lines," Infect. Immun. 61:3664-3672 (1993).
 - Anderson et al., J. Am.Chem. Soc. 85: 3039 (1963).
 - Ashborn et al., "Anti-HIV Activity of CD4-Pseudomonas Exotoxin on Infected Primary Lymphocytes and Monocyte/Macrophages," J. Infect. Dis. 163: 703-709 (1991).
 - Baer, Can. J. Biochem. Phys. 34: 288-304 (1955).
 - Bai and Amidon, "Structural Specificity of Mucosal-Cell Transport and Metabolism of P Drugs: Implications for Oral Peptide Drug Delivery," Pharm. Res. 9: 969-978 (1992).
 - Bai et al., "Utilization of Peptide Carrier System to Improve Intestinal Absorption: Targ Prolidase as a Prodrug-Converting Enzyme," J. Pharm. Sci. 81: 113-116 (1992).
 - Barlow et al., "Mast cells and T lymphocytes in chronic urticaria," Clinical & Experimental Immunology 25: 317-322 (1995).
 - Baroni et al., "Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistology, Hybridization, and Identification of Target Cells," Am. J. Pathol. 133: 498-506 (1988).
 - Berdel et al., Lipids 22: 943-946 (1987).
 - Bickel et al., "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc. Natl. Acad. Sci. USA 90: 2618-2622 (1993).
 - Blakey, "Drug Targeting with Monoclonal Antibodies," Acta Oncol. 31: 91-97 (1992).
 - Blight et al., "Detection of hepatitis C virus RNA by in situ hybridization," Liver 12: 286 (1992).
 - Blum et al., "Blood clearance and organ deposition of intravenously administered microparticles: the effects of particle size, nature and shape," Int. J. Pharm. 12: 135-146 (1982).
 - Boehnlein et al., "Characterization of Esterase and Alcohol Dehydrogenase Activity in Metabolism of Retinyl Palmitate to Retinol (Vitamin A) During Percutaneous Absorption," Pharmaceutical Research 11: 1155-1159 (1994).
 - Boman et al., "Cell-free immunity in Cecropia: A model system for antibacterial protein synthesis," Biochem. 201: 23-31 (1990).
 - Borissova et al., "Biodegradable Microspheres. 17. Lysosomal Degradation of Primaq Spacer Arms," Journal of Pharmaceutical Sciences, vol. 84, No. 2, Feb. 1995, pp. 256-262.
 - Bou-Gharios et al., "Expression of ectopeptidases in scleroderma," Annals of Rheumatism 54: 111-116 (1995).
 - Brewster et al., "Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β -Cyclodextrins," J. Pharm. Sci. 77: 981-985 (1985).
 - Bromberg et al., "Detection of Bordetella pertussis Associated with the Alveolar Macrophages in Children with Human Immunodeficiency Virus Infection," Infect. Immun. 59: 4715-4719 (1991).
 - Brown & Silviu, Biochim. Biophys. Acta 1023: 341-351 (1990).
 - Brown et al., "Induction of Cell Surface Peptidase Activity: A Global Response to Cell Death Correlated with Apoptosis," J. Cellular Biochemistry 54: 320-331 (1994).
 - Brynestad et al., J. Virol. 64:680-685 (1990).

- Buchmeier and Heffron, "Induction of Salmonella Stress Proteins upon Infection of Mice," *Science* 248: 730-732 (1990).
- Buyuktimkin et al., "Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino) on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone," *Pharm Research* 10: 1632-1637 (1993).
- Chang, "Leishmania donovani: Promastigote-Macrophage Surface Interactions in Vitro," *Parasitol.* 48:175-189 (1979).
- Clarke et al., "Detection of HIV-1 in human lung macrophages using the polymerase chain reaction," *AIDS* 4: 1133-1136 (1990).
- Comiskey & Heath, *Biochim. Biophys. Acta* 1024: 307-317 (1990).
- Cordier et al., "In vivo Activation of Alveolar Macrophages in Ovine Lentivirus Infection," *Immunol. Immunopathol.* 55: 355-367 (1990).
- Couveur and Puisieux, "Nano-and microparticles for the delivery of polypeptides and proteins," *Adv. Drug Deliv. Rev.* 10: 141-162 (1993).
- Dachun et al., "Localization and Quantification of the Nonspecific Esterase in Injured Skin Following the Timing of Wounds," *Forensic Science International* 53: 203-213 (1992).
- De Magistris et al., "Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of the T Cell Receptor," *Cell* 68: 625-634 (1992).
- Debs et al., *Biochim. Biophys. Acta* 901: 183-190 (1987).
- Deres et al., *Nature* 342:561-564 (1989).
- Dreyer et al., *Proc. Natl. Acad. Sci. USA* 86: 9752-9756 (1989).
- Duncan, "Drug-polymer conjugates: potential for improved chemotherapy," *Anticancer Research* 12: 175-210 (1992).
- Elliott et al., "Naturally processed peptides," *Nature* 348: 195-197 (1990).
- Embretson et al., "Massive covert infection of helper T lymphocytes and macrophages during the incubation period of AIDS," *Nature* 362: 359-361 (1993).
- Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," *Nature* 351: 290-291 (1991).
- Falk et al., "Cellular peptide composition governed by major histocompatibility complex molecules," *Nature* 348: 248-251 (1990).
- Faulk et al., "Transferrin-Adriamycin Conjugates which Inhibit Tumor Cell Proliferation and Interaction with DNA Inhibit Plasma Membrane Oxidoreductase and Proton Release in K562 Cells," *Biochem. Int.* 25: 815-822 (1991).
- Faustman et al., "Linkage of Faulty Major Histocompatibility Complex Class I to Autoimmune Diabetes," *Science* 254: 1756-1776 (1991).
- Franssen et al., "Low Molecular Weight Proteins as Carrier for Renal Drug Targeting: Synthesis of Drug-Protein Conjugates and Drug-Spacer Derivatives and Their Catabolism in Renal Homogenates and Lysosomal Lysates," *J. Med. Chem.* 35: 1246-1259 (1992).
- Frehel et al., "Intramacrophage Growth of Mycobacterium avium during Infection of Mice," *Immun. Rev.* 59: 2207-2214 (1991).
- Friedman et al., "Uptake and Intracellular Survival of Bordetella pertussis in Human Macrophages," *Infect. Immun.* 60: 4578-4585 (1992).
- Frisch et al., "Parameters affecting the immunogenicity of a liposome-associated synthetic hexapeptide antigen," *Eur. J. Immun.* 21: 185-193 (1991).
- Gaspar et al., "Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani," *Ann. Trop. Parasitol.* 86: 41-49 (1992).
- Gendelman et al., "Slow, persistent replication of lentiviruses: Role of tissue macrophage precursors in bone marrow," *Proc. Natl. Acad. Sci. USA* 82: 7086-7090 (1985).
- Germain & Hendrix, "MHC class II structure, occupancy and surface expression determine post-endoplasmic reticulum antigen binding," *Nature* 353: 134-139 (1991).
- Groisman et al., "Resistance to host antimicrobial peptides is necessary for Salmonella survival within macrophages," *Proc. Natl. Acad. Sci. USA* 89: 11939-11943 (1992).
- Guery et al., "Selective Immunosuppression by Administration of Major Histocompatibility Complex (MHC) Class II-binding Peptides. I. Evidence for In Vivo MHC Blockade Preventing


Activation," J. Exp. Med. 175: 1345-1352 (1992).

- Halstead et al., "Dengue Viruses and Mononuclear Phagocytes: I. Infection Enhancement by Neutralizing Antibody," J. Exp. Med. 146:201-217 (1977).
- Hashimoto et al., Biochim. Biophys. Acta 816: 163-168 (1985).
- Hashimoto et al., Biochim. Biophys. Acta 816: 169-178 (1985).
- Heath and Martin, Chem. Phys. Lipids 40: 347-358 (1986).
- Heath et al., Biochim. Biophys. Acta 862: 72-80 (1986).
- Heath, Methods in Enzymol. 149: 111-119.
- Heinrich et al., "In-vivo Release of a GnRH Agonist from a Slow-release Poly(lactide-glycolide) Copolymer Preparation: Comparison in Rat, Rabbit and Guinea-Pig," J. Pharm. Pharmacol. 42: 765 (1991).
- Henrikus and Kampffmeyer, "Ester hydrolysis conjugation reactions in intact skin and homogenate, and by liver esterase of rabbits," Xenobiotica 22: 1357-1366 (1992).
- Heymann et al., "Organophosphate Sensitive and Insensitive Carboxylesterases in Human Cells," Biochem. Biophys. Res. Commun. 199: 217-226 (1993).
- Hopp, "Immunogenicity of a Synthetic HBsAg Peptide: Enhancement by Conjugation with an Acid Carrier," Mol. Immunol. 21: 13-16 (1984).
- Horwitz and Maxfield, "Legionella pneumophila Inhibits Acidification of its Phagosome in Human Monocytes," J. Cell Biol. 99: 1936-1943 (1984).
- Horwitz, "Interactions between Macrophages and Legionella pneumophila," Curr. Top. Microbiol. Immunol. 181:265-282 (1992).
- Horwitz, "The Legionnaires' Disease Bacterium (Legionella pneumophila) Inhibits Phagosome Lysosome Fusion in Human Monocytes," J. Exp. Med. 158: 2108-2126 (1983).
- Hostetler et al., J. Biol. Chem. 265: 6112-6117 (1990).
- Hunter et al., "Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral Leishmaniasis," J. Pharm. Pharmacol. 40 (1988).
- Jacobson et al., FEBS Lett. 225: 97-102 (1987).
- Jardetzky et al., "Identification of self peptides bound to purified HLA-B27," Nature 351 (1991).
- Jones and Hirsch, "The Interaction between Toxoplasma gondii and Mammalian Cells," J. Protozool. 136:1173-1194 (1972).
- Kanno et al., "Aleutian Mink Disease Parvovirus Infection of Mink Peritoneal Macrophage Human Macrophage Cell Lines," J. Virol. 67:2075-2082.
- Kanno et al., "Identification of Aleutian Mink Disease Parvovirus Transcripts in Macrophages Infected Adult Mink," J. Virol. 66:5305-5312 (1992).
- King et al., "In Vivo Selection of Lymphocyte-Tropic and Macrophage-Tropic Variants of Lymphocytic Choriomeningitis Virus during Persistent Infection," J. Virol. 64: 5611-5616 (1990).
- Kinsky & Loeder, Biochim. Biophys. Acta 921: 96-103 (1987).
- Kinsky et al., Biochim. Biophys. Acta 885: 129-135 (1986).
- Kinsky et al., Biochim. Biophys. Acta 917: 211-218 (1987).
- Kishimoto, Chem. Phys. Lipids 15: 33-36 (1975).
- Koenig et al., "Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy," Science 233: 1089-1093 (1986).
- Kondo et al., "Latent human herpesvirus 6 infection of human monocytes/macrophages," J. Virol. 72: 1401-1408 (1991).
- Koval & Pagano, "Lipid Recycling between the Plasma Membrane and Intracellular Compartments: Transport and Metabolism of Fluorescent Sphingomyelin Analogues in C6 Fibroblasts," J. Cell Biol. 108: 2169-2181 (1989).
- Kratz et al., "Keratinocyte conditioned medium stimulates type IV collagenase synthesis in cultured human keratinocytes and fibroblasts," Brit. J. Dermatology 133: 842-846 (1995).
- Kreeger, The Scientist, Sep. 16, 1996, p. 6.
- Krowka et al., J. Immunol. 144: 2535-2540 (1990).
- Kubota et al., "Metabolism and Degradation of Betamethasone 17-Valerate in Human Living Skin Equivalent," Dermatology 188: 13-17 (1994).

- Kung and Redemann, *Biochim. Biophys. Acta* 862: 435-439 (1986).
- Lamont et al., "The use of Peptide Analogs with Improved Stability and MHC Binding Inhibit Antigen Presentation In Vitro and In Vivo," *J. Immunol.* 144: 2493-2498 (1990).
- Lanzavecchia et al., "Irreversible association of peptides with class II MHC molecules cells," *Nature* 357: 249-252 (1992).
- Larsen et al., "Stability of ketoprofen-dextran ester prodrugs in homogenates of various of the pig GI tract," *Acta Pharm. Nord.* 3: 41-44 (1991).
- Lee et al., "Antibacterial peptides from pig intestines: Isolation of a mammalian cecrop Natl. Acad. Sci. USA 86: 9159-9162 (1989).
- Lehninger, *Biochemistry*, 2d ed., Chapters 11 & 24, Worth Publishers: New York, 197
- Lehrer et al., "Defensins: Endogenous Antibiotic Peptides of Animal Cells," *Cell* 64: 22 (1991).
- Lin et al., "Preparation of Enteric-Coated Microspheres of mycoplasma hyopneumoniae cellulose acetate; (ii) effect of temperature and pH on the stability and release behaviour microspheres," *Journal of Microencapsulation*, vol. 8, No. 4: 537-545 (1991).
- Lipozencic et al., "Langerhans cells in the immunopathology of contact allergic derma *Histochem* 38: 303-310 (1994).
- Loughery et al., *J. Immunol. Methods* 132: 25-35 (1990).
- MacDonald, *J. Biol. Chem.* 265: 13533-13539 (1990).
- Maciejewski et al., "Infection of Mononucleated Phagocytes with Human Cytomegalovirus 195: 327-336 (1993).
- Matsura et al., *J. Chem. Soc. Chem. Comm.* xx: 451-459 (1976).
- Mauel et al., "Quantitative Release of Live Micro-organisms from Infected Macrophage Sodium Dodecyl Sulfate," *Nature New Biol.* 244:93-94 (1973).
- Mauel, "Macrophage-Parasite Interactions in Leishmania Infections," *J. Leukocyte Biol* 193 (1990).
- McEntee et al., "Rhesus monkey macrophages infected with simian immunodeficiency cause rapid lysis of CD4-bearing lymphocytes," *J. Gen. Virol.* 72: 317-324 (1991).
- Meltzer and Gendelman, "Mononuclear Phagocytes as Targets, Tissue Reservoirs, and Immunoregulatory Cells in Human Immunodeficiency Virus Disease," *Curr. Topics Micro Immunol.* 181: 239-263 (1992).
- Menger et al., "Synthesis of a Lipid/Peptide/Drug Conjugate: N4-(Acylpeptidyl)-ARA-C Bioconjugate Chemistry 5: 162-166 (1994).
- Moehrle et al., "Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin histochemical study," *J. Cutaneous Pathology* 22: 241-247 (1995).
- Mukherjee & Heidelberger, *Cancer Res.* 22: 815-822 (1962).
- Murray et al., "Experimental Visceral Leishmaniasis: Production of Interleukin 2 and In Tissue Immune Reaction, and Response to Treatment with Interleukin 2 and Interferon γ Immunol. 138: 2290-2296 (1987).
- Narayan et al., "Lentivirus Induced Arthritis in Animals," *J. Rheumatol.* 32:25-32 (1992)
- Negre et al., "Antileishmanial Drug Targeting through Glycosylated Polymers Specific Internalized by Macrophage Membrane Lectins," *Antimicrob. Agents and Chemother.* 36 (1992).
- Neto et al., *Biochem. Biophys. Res. Commun.* 171: 458-464 (1990).
- Ng & Heath, *Biochim. Biophys. Acta* 981: 261-268 (1989).
- Nogueira and Cohn, "Trypanosoma cruzi: Mechanisms of Entry and Intracellular Fate Mammalian Cells," *J. Exp. Med.* 143:1402-1420 (1976).
- Nothnagel, *Biochim. Biophys. Acta* 980: 209-219 (1989).
- Pagano et al., *J. Biol. Chem.* 258: 2034-2040 (1983).
- Panuska et al., "Productive Infection of Isolated Human Alveolar Macrophages by Respiratory Syncytial Virus," *J. Clin. Invest.* 86: 113-119 (1990).
- Pardridge, "Opioid Peptide Drug Development: Transport of Opioid Chimeric Peptides Blood-Brain Barrier," *NIDA Res. Monograph* 120: 153-168 (1992).
- Parham, "Transporters of delight," *Nature* 348: 674-675 (1990).
- Paul and Anderson, *J. Am. Chem. Soc.* 82: 4596-4600 (1960).

- Payne et al., "Phagocytosis of *Legionella pneumophila* is Mediated by Human Monoc Complement Receptors," *J. Exp. Med.* 166: 1377-1389 (1987).
- Rahman et al., *Life Sci.* 31: 2061-2071 (1982).
- Remy et al., *J. Org. Chem.* 27: 2491-2500 (1962).
- Rosenberg et al., *J. Neurochem.* 48: 865-875 (1987).
- Rowlinson-Busza and Epenetos, "Targeted delivery of biologic and other antineoplast *Curr. Opin. Oncol.* 4: 1142-1148 (1992).
- Rubinstein et al., "In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Delivery Carrier," *Pharm. Res.* 10: 258-263 (1993).
- Sadegh-Nasseri and Germain, "A role for peptide in determining MHC class II structur *353: 167-170* (1991).
- Saffran et al., "A New Approach to the Oral Administration of Insulin and Other Peptid *Science* 233: 1081-1084 (1986).
- Salord et al., *Biochim. Biophys. Acta* 886: 64-75 (1986).
- Schlessinger and Horwitz, "Phagocytosis of Leprosy Bacilli is Mediated by Compleme Receptors CR1 and CR3 on Human Monocytes and Complement Component C3 in Ser *Invest.* 85: 1304-1314 (1990).
- Schmitt et al., "Multiplication of Human Immunodeficiency Virus in Primary Cultures o Kupffer Cells—Possible Role of Liver Macrophage Infection in the Physiopathology of AID *Virol.* 141: 143-152 (1990).
- Schnorr et al., "MxA-Dependent Inhibition of Measles Virus Glycoprotein Synthesis in Transfected Human Monocytic Cell Line," *J. Virol.* 67: 4760-4768 (1993).
- Seifert et al., *Biochem. J.* 267:795-802 (1990).
- Sellon et al., "Wild-Type Equine Infectious Anemia Virus Replicates in Vivo Predomin Tissue Macrophages, Not in Peripheral Blood Monocytes," *J. Virol.* 66: 5906-5913 (1992).
- Senter et al., "Activation of Prodrugs by Antibody-Enzyme Conjugates," in *Immunobio Peptides and Proteins*, vol. VI, pp. 97-105 (1991).
- Shanley and Pesanti, "Murine Peritoneal Macrophages Support Murine Cytomegalovi Replication," *Infect. Immunol.* 41: 1352-1359 (1983).
- Shen et al., "Cis-Aconityl Spacer between Daunomycin and Macromolecular Carriers: pH Sensitive Linkage Releasing Drug from a Lysomotropic Conjugate," *Biochem. Biophys Commun.* 102:1048-1052 (1981).
- Sierra-Honigman et al., "Borna disease virus in peripheral blood mononuclear and bo cells of neonatally and chronically infected rats," *J. Neuroimmunol.* 45: 31-36 (1993).
- Sintov et al., "Enzymatic cleavage of disaccharaide side groups in insoluble synthetic new method for specific delivery of drugs to the colon," *Biomaterials* 14: 483-490 (1993).
- SivaSai et al., "Effect of Recombinant Interferon Gamma Administration on Lesional Monocytes/Macrophages in Lepromatous Leprosy Patients," *Int. J. Leprosy & Other Myc Diseases* 61: 259-269 (1993).
- Small, "From alkanes to phospholipids," *Handbook of Lipid Research: Physical Chem Lipids*, vol. 4, Chapters 4 and 12, Plenum Press: New York, 1986.
- Smith and Khorana, *J. Amer. Chem. Soc.* 80: 1141-1145 (1958).
- Steim et al., *Biochem. Biophys. Res. Commun.* 171: 451-457 (1990).
- Strellrecht-Broomhall, "Evidence for Immune-Mediated Destruction as Mechanism for Induced Anemia in Persistently Infected Mice," *Viral Immunol.* 4: 269-280 (1991).
- Sturgill-Koszycki et al., "Lack of Acidification in Mycobacterium Phagosomes Produce Exclusion of the Vesicular Proton-ATPase," *Science* 263: 678-681 (1994).
- Trouet et al., "A covalent linkage between daunorubicin and proteins that is stable in s reversable by lysosomal hydrolases, as required for a lysomotropic drug-carrier conjuga and in vivo studies," *Proc. Natl. Acad. Sci. USA* 79:626-629 (1982).
- van Wijk et al., *Biochim. Biophys. Acta* 1084: 307-310 (1991).
- Vandenbark et al., *Nature* 341:841-844 (1989).
- Verbloom et al., *Synthesis* 1032: 807-809 (1981).
- Wada et al., "Salt Formation of Lactic Acid Oligomers as Matrix for Sustained Release *J. Pharm. Pharmacol.* 43: 605-608 (1991).

- Wiesmuller et al., "The antibody response in BALB/c mice to the Plasmodium falcipar circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant," 109-113 (1991).
- Wyrick and Brownridge, "Growth of Chlamydia psittaci in Macrophages," Infect. Immu 19:1054-1060 (1978).
- Yatvin et al., "Targeting Lipophilic Prodrugs to Brain, Lung, and Spleen," Journal of Ce Biochemistry, vol. 0, No. 19A: 173 (1995).
- Yatvin, "A Multi-Modality Approach for the Treatment of AIDS," Select. Cancer. Thera 28 (1991).
- Zasloff, "Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor," Proc. N Sci USA 84: 5449-5453 (1987).
- Zhang and McCormick, "Uptake of N-(4'-pyridoxyl)amines and release of amines by re model for transporter-enhanced delivery of bioactive compounds," Proc. Natl. Acad. Sci. 10407-10410 (1991).




[Nominate this for the Galle](#)



RESEARCH
PRODUCTS
INSIDE DELPHION

Search
More Files
Search Settings
My Account / Preferences
Search / Submit / Print / Contact Us / Help / About Us

The Delphion Integrated View

Buy Now:  [PDF](#) | [More choices...](#)


Tools: [Citation Link](#) | [Add to Work File:](#) [Create new Work File](#)

View: [Expand Details](#) | [INPADOC](#) | **Jump to:** Top

Go to: [Derwent](#)

[Email](#)

- 🔍 **Title:** **US6063759: Conjugate of biologically active compound and polar lip conjugated to a microparticle for biological targeting**
 [[Derwent Title](#)]
- 🔍 **Country:** **US** United States of America
- 🔍 **Inventor:** **Yatvin, Milton B.**; Portland, OR
Stowell, Michael H B; Fulbourn, United Kingdom
Gallicchio, Vincent S.; Lexington, KY
Meredith, Michael J.; Lake Oswego, OR
- 🔍 **Assignee:** **Oregon Health Sciences University**, Portland, OR
 other patents from [OREGON HEALTH SCIENCES UNIVERSITY](#)
[\(420630\)](#) (approx. 161)
[News, Profiles, Stocks and More about this company](#)
- 🔍 **Published / Filed:** **2000-05-16 / 1998-04-14**
- 🔍 **Application Number:** **US1998000060011**
- 🔍 **IPC Code:** **A01N 37/18**; **A61K 9/127**; **A61K 47/00**; **C12N 5/08**; **C07K 17/00**;
- 🔍 **ECLA Code:** **C07H19/06E**; **C07H19/10E**;
- 🔍 **U.S. Class:** **514/002**; **424/450**; **435/176**; **435/178**; **435/179**; **435/180**; **435/325**;
435/366; **530/300**; **530/329**; **530/331**; **530/811**; **530/813**; **530/814**;
530/815;
- 🔍 **Field of Search:** **514/002** **424/450** **536/051**,78,28.2 **436/518**,528
530/300,331,329,810,815,811,813,814
435/174,180,325,366,176,178,179
- 🔍 **Government Interest:** This invention was made with government support under grant 1-R01-CA49416 by the National Institutes of Health. The government has certain rights in the invention.
- 🔍 **Priority Number:** 1998-04-14 **US1998000060011**
 1996-08-01 **US1996000691891**
 1995-05-16 **US1995000441770**
 1994-05-19 **US1994000246941**
 1993-10-26 **US1993000142771**
 1992-07-09 **US1992000911209**
 1990-11-01 **US1990000607982**
- 🔍 **Abstract:** Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a



microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

⚡ Attorney, Agent or Firm: **McDonnell Boehnen Hulbert & Berghoff ;**

⚡ Primary / Assistant Examiner: **Naff, David M.;**

⚡ INPADOC

None

Buy Now: [Family Legal Status Report](#)

Legal Status:

⚡ Related Applications:

Go to Result Set: 1 patent(s) that list this one as related

Application Number	Filed	Patent	Pub. Date	Title
US1996000691891	1996-08-01	US5840674	1998-11-24	Covalent microparticle-drug conjugates for biological ta
US1995000441770	1995-05-16	US5543391	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1994000246941	1994-05-19	US5543390	1996-08-06	Covalent microparticle-drug conjugates for biological ta
US1993000142771	1993-10-26	US5543389	1996-08-06	Covalent polar lipid-peptide conjugates for use in salve
US1992000911209	1992-07-09	US5256641	1993-10-26	Covalent polar lipid-peptide conjugates for immunologic targeting
US1990000607982	1990-11-01	US5149794	1992-09-22	Covalent lipid-drug conjuga drug targeting

⚡ Parent Case:

This application is a continuation of application Ser. No. 08/691,891, filed Aug. 1, 1996, now U.S. Pat. No. 5,840,674, which is a continuation of application Ser. No. 08/441,770, filed May 16, 1995, now U.S. Pat. No. 5,543,391, which is a continuation of application Ser. No. 08/246,941, filed May 19, 1994, now U.S. Pat. No. 5,543,390, which is a continuation-in-part of application Ser. No. 08/142,771, filed Oct. 26, 1993, now U.S. Pat. No. 5,543,389, which is a continuation-in-part of application Ser. No. 07/911,209, filed Jul. 9, 1992, now U.S. Pat. No. 5,256,641, which is a continuation-in-part of application Ser. No. 07/607,982, filed Nov. 1, 1990, now U.S. Pat. No. 5,149,794, the disclosures of each of which are herein incorporated by reference in its entirety.

⚡ Designated Country:

AM AP BB BG BR BY CA CN CZ EE FI GE HU IS KE KG KP KR KZ LK LR LT LV BE
FR GB GR IE IT LI LU MC

Family: [Show 24 known family members](#)

First Claim: [Show all 69 claims](#)

What is claimed is:

1. A composition of matter comprising a prodrug of a biologically-active compound, a microparticle and a cleavable linker moiety comprising two linker functional groups, wherein the cleavable linker moiety has a first end and a second end and wherein the microparticle is attached to the first end of the linker moiety through a first linker functional group and the prodrug attached to the second end of the linker moiety through a second linker functional group, and wherein the cleavable linker moiety is non-specifically cleaved inside a phagocytic mammalian cell, and wherein the prodrug comprises a biologically active compound, a polar lipid moiety comprised of one or a plurality of polar lipid molecules and a specific linker moiety, wherein the specific linker moiety is covalently linked to both the biologically active compound and the polar lipid moiety, wherein the specific linker moiety is specifically cleaved in a phagocytic mammalian cell infected with a microorganism and is specifically activated thereby.








Background / Summary: [Show background / summary](#)





Drawing Descriptions: [Show drawing descriptions](#)

Description: [Show description](#)








Forward References: [Show 2 U.S. patent\(s\) that reference this one](#)













U.S. References: [Go to Result Set: All U.S. references](#) | [Forward references \(2\)](#) | [Backward references](#)
[Citation Link](#)



Buy PDF	Patent	Pub.Date	Inventor	Assignee	Title
	US4780455	1988-10	Liberman et al.	The Trustees of Columbia University in the City of New York	Lipophilic compounds for pharmacological and organic compounds
	US4793986	1988-12	Serino et al.	Johnson Matthey, Inc.	Macromolecular antitumor compounds
	US4847240	1989-07	Ryser et al.	The Trustees of Boston University	Method of effecting uptake of molecules
	US5053394	1991-10	Ellestad et al.	American Cyanamid Company	Targeted forms of methylthio agents
	US5149794	1992-09	Yatvin et al.	State of Oregon	Covalent lipid-drug conjugates for drug targeting
	US5256641	1993-10	Yatvin et al.	State of Oregon	Covalent polar peptide conjugates for immunological targeting
	US5258453	1993-11	Kopecek et al.	University of Utah	Drug delivery system for the simultaneous delivery of drugs and activation of enzymes and ligands
				State of Oregon, Acting by and Through the Oregon State	Covalent polar

	US5543389	1996-08	Yatvin et al.	Board of Higher Education on Behalf of the Oregon Health Sciences University, a non profit organization	<u>peptide conjugates in salves</u>
	US5543390	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	<u>Covalent microparticle drug conjugates biological target</u>
	US5543391	1996-08	Yatvin et al.	State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University	<u>Covalent microparticle drug conjugates biological target</u>
	US5840674	1998-11	Yatvin et al.	Oregon Health Sciences University	<u>Covalent microparticle drug conjugates biological target</u>

Foreign
References:

Buy PDF	Publication	Date	IPC Code	Assignee	Title
	EP0077529	1983-04	C07C 93/187	Sanol Schwarz GmbH	<u>Medicinal form</u>
	EP0109484	1983-04	G08B 21/00	Trampnau, Ulrich	<u>Warning device for helicopters</u>
	EP0203676	1986-12	A61K 39/12	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	<u>Vaccine for generation of immunogenic response protein against a virus</u>
	EP0279887	1988-08	C07C 101/30	Kesner, Leo	<u>Carnitine derivatives, pharmaceuticals and their use for manufacture of medicament for treatment of metabolic disorder</u>
	WO8911299	1989-11	A61K 49/00	STATE OF OREGON acting by and through THE STATE ...	<u>METHOD FOR DELIVERY OF THERAPEUTIC TO TARGET BLOOD TISSUE USING MONOCLONAL ANTIBODY CONJUGATES</u>
	WO8910348	1989-11	C07C 99/10	GIBBONS, William, Anthony	<u>FATTY AMINO ACID AND HOMO- AND HETERO-OLIGOMER AND CONJUGATES THEREOF</u>
	WO9000555	1990-01	C07H 15/12	VICAL, INC.	<u>LIPID DERIVATIVES ANTIVIRAL NUCLEOSIDE LIPOSOMAL INCORPORATION METHOD OF</u>
					<u>COVALENT CONJUGATES</u>

	WO9010448	1990-09	A61K 31/70	GENENTECH, INC.	<u>AND OLIGONUCLE</u>
	WO9101750	1991-02	A61K 39/02	UNIVAX BIOLOGICS INCORPORATED	<u>LIPID A ANALOG/IMM CARRIER CO AND THE USE AS VACCINES</u>
	WO9116024	1991-10	A61F 13/00	VICAL, INC.	<u>CATIONIC LIP INTRACELLU DELIVERY OF BIOLOGICALL MOLECULES</u>
	WO9119726A	1991-12	C07H 17/00	KUCERA, Louis, S.	<u>ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES</u>
	WO9401131	1994-01	A61K 39/00	EUKARION, INC.	<u>TRANSVASCUL INTRACELLU DELIVERY OF PROTEINS</u>
	WO9401138	1994-01	A61K 47/48	STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION on behalf of the OREGON HEALTH SCIENCES UNIVERSITY	<u>COVALENT P LIPID-PEPTID CONJUGATES BIOLOGICAL TARGETING</u>
	WO9402178	1994-02	A61K 47/48	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as	<u>TARGETING O LIPOSOMES T BLOOD-BRAIN BARRIER</u>
	WO9403424	1994-02	C07C 323/41	DRUG DELIVERY SYSTEM INSTITUTE, LTD.	<u>COMPOUND OF INTRACER RESIDENCE A THEREOF</u>
	WO9406450	1994-03	A61K 37/00	UNIVERSITY OF FLORIDA	<u>BRAIN-ENHANC DELIVERY OF NEUROACTIV PEPTIDES BY SEQUENTIAL METABOLISM</u>
	WO9425616	1994-11	C12P 21/00	WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY	<u>CELL-TARGET PORE-FORMING AGENTS</u>
	WO9507092	1995-03	A61K 38/00	THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY	<u>BLOOD-BRAIN TRANSPORT OF NEUROLOGIC AGENTS</u>
	WO9522963	1995-08	A61K 9/51	MEDINOVA MEDICAL CONSULTING GMBH	<u>DRUG TARGETING SYSTEM, METHOD PREPARING SAME AND ITS USE</u>
	WO9532002	1995-11	A61K 47/48	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH	<u>COVALENT MICROPARTICLE CONJUGATES BIOLOGICAL TARGETING</u>

				SCIENCES UNIVERSITY	
	WO9604001	1996-02	A61K 38/00	MOLECULAR/STRUCTURAL BIOTECHNOLOGIES, INC.	SITE-SPECIFIC BIOMOLECULAR COMPLEXES
	WO9622303	1996-07	C07J 5/00	BENDER, Veronika, Judith	THERAPEUTIC COMPOUND ACID CONJUGATE

Other Abstract Info: CHEMABS 118(04)027456V CHEMABS 120(24)307470P CHEMABS 124(14)185548E 125(16)204546S CHEMABS 125(18)230787R CHEMABS 129(25)335730C DERABS C 340298 DERABS C1993-350862 DERABS C1996-020359

- Other References:
- Abbas et al., "Antigen Presentation and T Cell Antigen Recognition," Cellular as J. Mo (W.B. Saunders Co.; Philadelphia), pp. 116-136.
 - Afzelius et al., Biochim. Biophys. Acta 979: 231-238 (1989).
 - Alvarez-Dominquez et al., "Role of Complement Component C1q in Phagocytosis of L monocytogenes by Murine Macrophage-Like Cell Lines," Infect. Immun. 61:3664-3672 (1993).
 - Anderson et al., J. Am.Chem. Soc. 85: 3039 (1963).
 - Ashborn et al., "Anti-HIV Activity of CD4-Pseudomonas Exotoxin on Infected Primary Lymphocytes and Monocyte/Macrophages," J. Infect. Dis. 163: 703-709 (1991).
 - Baer, Can. J. Biochem. Phys. 34: 288-304 (1955).
 - Bai and Amidon, "Structural Specificity of Mucosal-Cell Transport and Metabolism of P Drugs: Implications for Oral Peptide Drug Delivery," Pharm. Res. 9: 969-978 (1992).
 - Bai et al., "Utilization of Peptide Carrier System to Improve Intestinal Absorption: Targ Prolidase as a Prodrug-Converting Enzyme," J. Pharm. Sci. 81: 113-116 (1992).
 - Barlow et al., "Mast cells and T lymphocytes in chronic urticaria," Clinical & Experimental Immunology 25: 317-322 (1995).
 - Baroni et al., "Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistochemical Hybridization, and Identification of Target Cells," Am. J. Pathol. 133: 498-506 (1988).
 - Berdel et al., Lipids 22: 943-946 (1987).
 - Bickel et al., "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc. Natl. Acad. Sci. USA 90: 2618-2622 (1993).
 - Blakey, "Drug Targeting with Monoclonal Antibodies," Acta Oncol. 31: 91-97 (1992).
 - Blight et al., "Detection of hepatitis C virus RNA by in situ hybridization," Liver 12: 286 (1992).
 - Blum et al., "Blood clearance and organ deposition of intravenously administered microparticles: the effects of particle size, nature and shape," Int. J. Pharm. 12: 135-146 (1982).
 - Boehnlein et al., "Characterization of Esterase and Alcohol Dehydrogenase Activity in Metabolism of Retinyl Palmitate to Retinol (Vitamin A) During Percutaneous Absorption," Pharmaceutical Research 11: 1155-1159 (1994).
 - Boman et al., "Cell-free immunity in Cecropia: A model system for antibacterial protein synthesis," Biochem. 201: 23-31 (1990).
 - Borissova et al., "Biodegradable Microspheres. 17. Lysosomal Degradation of Primaq Spacer Arms," Journal of Pharmaceutical Sciences, vol. 84, No. 2, Feb. 1995, pp. 256-262.
 - Bou-Gharios et al., "Expression of ectopeptidases in scleroderma," Annals of Rheumatism 54: 111-116 (1995).
 - Brewster et al., "Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β -Cyclodextrins," J. Pharm. Sci. 77: 981-985 (1985).
 - Bromberg et al., "Detection of Bordetella pertussis Associated with the Alveolar Macrophages in Children with Human Immunodeficiency Virus Infection," Infect. Immun. 59: 4715-4719 (1991).
 - Brown & Silviu, Biochim. Biophys. Acta 1023: 341-351 (1990).
 - Brown et al., "Induction of Cell Surface Peptidase Activity: A Global Response to Cell Death Correlated with Apoptosis," J. Cellular Biochemistry 54: 320-331 (1994).
 - Brynestad et al., J. Virol. 64:680-685 (1990).

- Buchmeier and Heffron, "Induction of Salmonella Stress Proteins upon Infection of Mice," *Science* 248: 730-732 (1990).
- Buyuktimkin et al., "Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino) on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone," *Pharm Research* 10: 1632-1637 (1993).
- Chang, "Leishmania donovani: Promastigote-Macrophage Surface Interactions in Vitro," *Parasitol.* 48:175-189 (1979).
- Clarke et al., "Detection of HIV-1 in human lung macrophages using the polymerase chain reaction," *AIDS* 4: 1133-1136 (1990).
- Comiskey & Heath, *Biochim. Biophys. Acta* 1024: 307-317 (1990).
- Cordier et al., "In vivo Activation of Alveolar Macrophages in Ovine Lentivirus Infection," *Immunol. Immunopathol.* 55: 355-367 (1990).
- Couveur and Puisieux, "Nano-and microparticles for the delivery of polypeptides and proteins," *Adv. Drug Deliv. Rev.* 10: 141-162 (1993).
- Dachun et al., "Localization and Quantification of the Nonspecific Esterase in Injured Skin: Timing of Wounds," *Forensic Science International* 53: 203-213 (1992).
- De Magistris et al., "Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of T Cell Receptor," *Cell* 68: 625-634 (1992).
- Debs et al., *Biochim. Biophys. Acta* 901: 183-190 (1987).
- Deres et al., *Nature* 342:561-564 (1989).
- Dreyer et al., *Proc. Natl. Acad. Sci. USA* 86: 9752-9756 (1989).
- Duncan, "Drug-polymer conjugates: potential for improved chemotherapy," *Anticancer Res.* 12: 175-210 (1992).
- Elliott et al., "Naturally processed peptides," *Nature* 348: 195-197 (1990).
- Embretson et al., "Massive covert infection of helper T lymphocytes and macrophage during the incubation period of AIDS," *Nature* 362: 359-361 (1993).
- Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," *Nature* 351: 290-291 (1991).
- Falk et al., "Cellular peptide composition governed by major histocompatibility complex molecules," *Nature* 348: 248-251 (1990).
- Faulk et al., "Transferrin-Adriamycin Conjugates which Inhibit Tumor Cell Proliferation and Interaction with DNA Inhibit Plasma Membrane Oxidoreductase and Proton Release in K562 Cells," *Biochem. Int.* 25: 815-822 (1991).
- Faustman et al., "Linkage of Faulty Major Histocompatibility Complex Class I to Autoimmune Diabetes," *Science* 254: 1756-1776 (1991).
- Franssen et al., "Low Molecular Weight Proteins as Carrier for Renal Drug Targeting: Evaluation of Drug-Protein Conjugates and Drug-Spacer Derivatives and Their Catabolism in Renal Homogenates and Lysosomal Lysates," *J. Med. Chem.* 35: 1246-1259 (1992).
- Frehel et al., "Intramacrophage Growth of Mycobacterium avium during Infection of Mice," *Immun. Rev.* 59: 2207-2214 (1991).
- Friedman et al., "Uptake and Intracellular Survival of Bordetella pertussis in Human Macrophages," *Infect. Immun.* 60: 4578-4585 (1992).
- Frisch et al., "Parameters affecting the immunogenicity of a liposome-associated synthetic hexapeptide antigen," *Eur. J. Immun.* 21: 185-193 (1991).
- Gaspar et al., "Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani," *Ann. Trop. Parasitol.* 86: 41-49 (1992).
- Gendelman et al., "Slow, persistent replication of lentiviruses: Role of tissue macrophage precursors in bone marrow," *Proc. Natl. Acad. Sci. USA* 82: 7086-7090 (1985).
- Germain & Hendrix, "MHC class II structure, occupancy and surface expression determine post-endoplasmic reticulum antigen binding," *Nature* 353: 134-139 (1991).
- Groisman et al., "Resistance to host antimicrobial peptides is necessary for Salmonella survival in macrophages," *Proc. Natl. Acad. Sci. USA* 89: 11939-11943 (1992).
- Guery et al., "Selective Immunosuppression by Administration of Major Histocompatibility Complex (MHC) Class II-binding Peptides. I. Evidence for In Vivo MHC Blockade Prevents


Activation," J. Exp. Med. 175: 1345-1352 (1992).

- Halstead et al., "Dengue Viruses and Mononuclear Phagocytes: I. Infection Enhancement by Neutralizing Antibody," J. Exp. Med. 146:201-217 (1977).
- Hashimoto et al., Biochim. Biophys. Acta 816: 163-168 (1985).
- Hashimoto et al., Biochim. Biophys. Acta 816: 169-178 (1985).
- Heath and Martin, Chem. Phys. Lipids 40: 347-358 (1986).
- Heath et al., Biochim. Biophys. Acta 862: 72-80 (1986).
- Heath, Methods in Enzymol. 149: 111-119.
- Heinrich et al., "In-vivo Release of a GnRH Agonist from a Slow-release Poly(lactide-g Copolymer Preparation: Comparison in Rat, Rabbit and Guinea-Pig," J. Pharm. Pharmacol. 42: 765 (1991).
- Henrikus and Kampffmeyer, "Ester hydrolysis conjugation reactions in intact skin and homogenate, and by liver esterase of rabbits," Xenobiotica 22: 1357-1366 (1992).
- Heymann et al., "Organophosphate Sensitive and Insensitive Carboxylesterases in Human Monocytes," J. Biol. Chem. 268: 217-226 (1993).
- Hopp, "Immunogenicity of a Synthetic HBsAg Peptide: Enhancement by Conjugation with an Acid Carrier," Mol. Immunol. 21: 13-16 (1984).
- Horwitz and Maxfield, "Legionella pneumophila Inhibits Acidification of its Phagosome in Human Monocytes," J. Cell Biol. 99: 1936-1943 (1984).
- Horwitz, "Interactions between Macrophages and Legionella pneumophila," Curr. Top. Immunol. 181:265-282 (1992).
- Horwitz, "The Legionnaires' Disease Bacterium (Legionella pneumophila) Inhibits Phagosome Lysosome Fusion in Human Monocytes," J. Exp. Med. 158: 2108-2126 (1983).
- Hostetler et al., J. Biol. Chem. 265: 6112-6117 (1990).
- Hunter et al., "Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral Leishmaniasis," J. Pharm. Pharmacol. 40 (1988).
- Jacobson et al., FEBS Lett. 225: 97-102 (1987).
- Jardetzky et al., "Identification of self peptides bound to purified HLA-B27," Nature 35 (1991).
- Jones and Hirsch, "The Interaction between Toxoplasma gondii and Mammalian Cells," J. Cell Biol. 136:1173-1194 (1972).
- Kanno et al., "Aleutian Mink Disease Parvovirus Infection of Mink Peritoneal Macrophage Human Macrophage Cell Lines," J. Virol. 67:2075-2082.
- Kanno et al., "Identification of Aleutian Mink Disease Parvovirus Transcripts in Macrophages Infected Adult Mink," J. Virol. 66:5305-5312 (1992).
- King et al., "In Vivo Selection of Lymphocyte-Tropic and Macrophage-Tropic Variants of Lymphocytic Choriomeningitis Virus during Persistent Infection," J. Virol. 64: 5611-5616 (1990).
- Kinsky & Loeder, Biochim. Biophys. Acta 921: 96-103 (1987).
- Kinsky et al., Biochim. Biophys. Acta 885: 129-135 (1986).
- Kinsky et al., Biochim. Biophys. Acta 917: 211-218 (1987).
- Kishimoto, Chem. Phys. Lipids 15: 33-36 (1975).
- Koenig et al., "Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy," Science 233: 1089-1093 (1986).
- Kondo et al., "Latent human herpesvirus 6 infection of human monocytes/macrophages," J. Virol. 72: 1401-1408 (1991).
- Koval & Pagano, "Lipid Recycling between the Plasma Membrane and Intracellular Compartments: Transport and Metabolism of Fluorescent Sphingomyelin Analogues in C2C12 Fibroblasts," J. Cell Biol. 108: 2169-2181 (1989).
- Kratz et al., "Keratinocyte conditioned medium stimulates type IV collagenase synthesis in cultured human keratinocytes and fibroblasts," Brit. J. Dermatology 133: 842-846 (1995).
- Kreeger, The Scientist, Sep. 16, 1996, p. 6.
- Krowka et al., J. Immunol. 144: 2535-2540 (1990).
- Kubota et al., "Metabolism and Degradation of Betamethasone 17-Valerate in Human Living Skin Equivalent," Dermatology 188: 13-17 (1994).

- Kung and Redemann, *Biochim. Biophys. Acta* 862: 435-439 (1986).
- Lamont et al., "The use of Peptide Analogs with Improved Stability and MHC Binding Inhibit Antigen Presentation In Vitro and In Vivo," *J. Immunol.* 144: 2493-2498 (1990).
- Lanzavecchia et al., "Irreversible association of peptides with class II MHC molecules cells," *Nature* 357: 249-252 (1992).
- Larsen et al., "Stability of ketoprofen-dextran ester prodrugs in homogenates of various of the pig GI tract," *Acta Pharm. Nord.* 3: 41-44 (1991).
- Lee et al., "Antibacterial peptides from pig intestines: Isolation of a mammalian cecrop Natl. Acad. Sci. USA 86: 9159-9162 (1989).
- Lehninger, *Biochemistry*, 2d ed., Chapters 11 & 24, Worth Publishers: New York, 197
- Lehrer et al., "Defensins: Endogenous Antibiotic Peptides of Animal Cells," *Cell* 64: 22 (1991).
- Lin et al., "Preparation of Enteric-Coated Microspheres of mycoplasma hyopneumoniae cellulose acetate; (ii) effect of temperature and pH on the stability and release behaviour microspheres," *Journal of Microencapsulation*, vol. 8, No. 4: 537-545 (1991).
- Lipozencic et al., "Langerhans cells in the immunopathology of contact allergic derma *Histochem* 38: 303-310 (1994).
- Loughery et al., *J. Immunol. Methods* 132: 25-35 (1990).
- MacDonald, *J. Biol. Chem.* 265: 13533-13539 (1990).
- Maciejewski et al., "Infection of Mononucleated Phagocytes with Human Cytomegalovirus 195: 327-336 (1993).
- Matura et al., *J. Chem. Soc. Chem. Comm.* xx: 451-459 (1976).
- Mauel et al., "Quantitative Release of Live Micro-organisms from Infected Macrophag Sodium Dodecyl Sulfate," *Nature New Biol.* 244:93-94 (1973).
- Mauel, "Macrophage-Parasite Interactions in Leishmania Infections," *J. Leukocyte Biol* 193 (1990).
- McEntee et al., "Rhesus monkey macrophages infected with simian immunodeficiency cause rapid lysis of CD4-bearing lymphocytes," *J. Gen. Virol.* 72: 317-324 (1991).
- Meltzer and Gendelman, "Mononuclear Phagocytes as Targets, Tissue Reservoirs, and Immunoregulatory Cells in Human Immunodeficiency Virus Disease," *Curr. Topics Micro Immunol.* 181: 239-263 (1992).
- Menger et al., "Synthesis of a Lipid/Peptide/Drug Conjugate: N4-(Acylpeptidyl)-ARA-C Bioconjugate Chemistry 5: 162-166 (1994).
- Moehrle et al., "Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin histochemical study," *J. Cutaneous Pathology* 22: 241-247 (1995).
- Mukherjee & Heidelberger, *Cancer Res.* 22: 815-822 (1962).
- Murray et al., "Experimental Visceral Leishmaniasis: Production of Interleukin 2 and In Tissue Immune Reaction, and Response to Treatment with Interleukin 2 and Interferon gamma Immunol. 138: 2290-2296 (1987).
- Narayan et al., "Lentivirus Induced Arthritis in Animals," *J. Rheumatol.* 32:25-32 (1992)
- Negre et al., "Antileishmanial Drug Targeting through Glycosylated Polymers Specific Internalized by Macrophage Membrane Lectins," *Antimicrob. Agents and Chemother.* 36 (1992).
- Neto et al., *Biochem. Biophys. Res. Commun.* 171: 458-464 (1990).
- Ng & Heath, *Biochim. Biophys. Acta* 981: 261-268 (1989).
- Nogueira and Cohn, "Trypanosoma cruzi: Mechanisms of Entry and Intracellular Fate Mammalian Cells," *J. Exp. Med.* 143:1402-1420 (1976).
- Nothnagel, *Biochim. Biophys. Acta* 980: 209-219 (1989).
- Pagano et al., *J. Biol. Chem.* 258: 2034-2040 (1983).
- Panuska et al., "Productive Infection of Isolated Human Alveolar Macrophages by Respiratory Syncytial Virus," *J. Clin. Invest.* 86: 113-119 (1990).
- Pardridge, "Opioid Peptide Drug Development: Transport of Opioid Chimeric Peptides Blood-Brain Barrier," *NIDA Res. Monograph* 120: 153-168 (1992).
- Parham, "Transporters of delight," *Nature* 348: 674-675 (1990).
- Paul and Anderson, *J. Am. Chem. Soc.* 82: 4596-4600 (1960).

- Payne et al., "Phagocytosis of *Legionella pneumophila* is Mediated by Human Monoc Complement Receptors," *J. Exp. Med.* 166: 1377-1389 (1987).
- Rahman et al., *Life Sci.* 31: 2061-2071 (1982).
- Remy et al., *J. Org. Chem.* 27: 2491-2500 (1962).
- Rosenberg et al., *J. Neurochem.* 48: 865-875 (1987).
- Rowlinson-Busza and Epenetos, "Targeted delivery of biologic and other antineoplast Curr. Opin. Oncol. 4: 1142-1148 (1992).
- Rubinstein et al., "In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Delivery Carrier," *Pharm. Res.* 10: 258-263 (1993).
- Sadegh-Nasseri and Germain, "A role for peptide in determining MHC class II structur 353: 167-170 (1991).
- Saffran et al., "A New Approach to the Oral Administration of Insulin and Other Peptid Science 233: 1081-1084 (1986).
- Salord et al., *Biochim. Biophys. Acta* 886: 64-75 (1986).
- Schlessinger and Horwitz, "Phagocytosis of Leprosy Bacilli is Mediated by Compleme Receptors CR1 and CR3 on Human Monocytes and Complement Component C3 in Ser Invest. 85: 1304-1314 (1990).
- Schmitt et al., "Multiplication of Human Immunodeficiency Virus in Primary Cultures o Kupffer Cells—Possible Role of Liver Macrophage Infection in the Physiopathology of AID Virol. 141: 143-152 (1990).
- Schnorr et al., "MxA-Dependent Inhibition of Measles Virus Glycoprotein Synthesis in Transfected Human Monocytic Cell Line," *J. Virol.* 67: 4760-4768 (1993).
- Seifert et al., *Biochem. J.* 267:795-802 (1990).
- Sellon et al., "Wild-Type Equine Infectious Anemia Virus Replicates in Vivo Predomin Tissue Macrophages, Not in Peripheral Blood Monocytes," *J. Virol.* 66: 5906-5913 (1992
- Senter et al., "Activation of Prodrugs by Antibody-Enzyme Conjugates," in *Immunobio Peptides and Proteins*, vol. VI, pp. 97-105 (1991).
- Shanley and Pesanti, "Murine Peritoneal Macrophages Support Murine Cytomegalovi Replication," *Infect. Immunol.* 41: 1352-1359 (1983).
- Shen et al., "Cis-Aconityl Spacer between Daunomycin and Macromolecular Carriers: pH Sensitive Linkage Releasing Drug from a Lysomotropic Conjugate," *Biochem. Biophys Commun.* 102:1048-1052 (1981).
- Sierra-Honigman et al., "Borna disease virus in peripheral blood mononuclear and bo cells of neonatally and chronically infected rats," *J. Neuroimmunol.* 45: 31-36 (1993).
- Sintov et al., "Enzymatic cleavage of disaccharaide side groups in insoluble synthetic new method for specific delivery of drugs to the colon," *Biomaterials* 14: 483-490 (1993).
- SivaSai et al., "Effect of Recombinant Interferon Gamma Administration on Lesional Monocytes/Macrophages in Lepromatous Leprosy Patients," *Int. J. Leprosy & Other Myc Diseases* 61: 259-269 (1993).
- Small, "From alkanes to phospholipids," *Handbook of Lipid Research: Physical Chem Lipids*, vol. 4, Chapters 4 and 12, Plenum Press: New York, 1986.
- Smith and Khorana, *J. Amer. Chem. Soc.* 80: 1141-1145 (1958).
- Steim et al., *Biochem. Biophys. Res. Commun.* 171: 451-457 (1990).
- Strellrecht-Broomhall, "Evidence for Immune-Mediated Destruction as Mechanism for Induced Anemia in Persistently Infected Mice," *Viral Immunol.* 4: 269-280 (1991).
- Sturgill-Koszycki et al., "Lack of Acidification in Mycobacterium Phagosomes Produce Exclusion of the Vesicular Proton-ATPase," *Science* 263: 678-681 (1994).
- Trouet et al., "A covalent linkage between daunorubicin and proteins that is stable in s reversable by lysosomal hydrolases, as required for a lysomotropic drug-carrier conjuga and in vivo studies," *Proc. Natl. Acad. Sci. USA* 79:626-629 (1982).
- van Wijk et al., *Biochim. Biophys. Acta* 1084: 307-310 (1991).
- Vandenbark et al., *Nature* 341:841-844 (1989).
- Verbloom et al., *Synthesis* 1032: 807-809 (1981).
- Wada et al., "Salt Formation of Lactic Acid Oligomers as Matrix for Sustained Release J. Pharm. Pharmacol. 43: 605-608 (1991).

- Wiesmuller et al., "The antibody response in BALB/c mice to the Plasmodium falcipar circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant," 109-113 (1991).
- Wyrick and Brownridge, "Growth of Chlamydia psittaci in Macrophages," Infect. Immu 19:1054-1060 (1978).
- Yatvin et al., "Targeting Lipophilic Prodrugs to Brain, Lung, and Spleen," Journal of Ce Biochemistry, vol. 0, No. 19A: 173 (1995).
- Yatvin, "A Multi-Modality Approach for the Treatment of AIDS," Select. Cancer. Thera 28 (1991).
- Zasloff, "Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor," Proc. N Sci USA 84: 5449-5453 (1987).
- Zhang and McCormick, "Uptake of N-(4'-pyridoxyl)amines and release of amines by re model for transporter-enhanced delivery of bioactive compounds," Proc. Natl. Acad. Sci. 10407-10410 (1991).



[Nominate this for the Galle](#)

[Home](#)


[R&D](#)

[Press Releases](#)

[Info](#)

[Publications](#)

[Contact](#)

[Entrez](#) [PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PMC](#)[Journals](#)[Books](#)Search for [Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)

Show:



Sort



Text Version

Entrez PubMed

[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)

PubMed Services

[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)

Related Resources

[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)

☐ 1: J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):193-203.

[Related Art](#)[L](#)

A lipidated anti-Tat antibody enters living cells and blocks HIV-viral replication.

Cruikshank WW, Doctrow SR, Falvo MS, Huffman K, Maciaszek J, Viglianti G, Raina J, Kornfeld H, Malfroy B.

Pulmonary Center, Boston University School of Medicine, Massachusetts, U.S.A.

We have developed a chemical modification of antibodies, lipidation, which enables their intracellular delivery into living cells. Intracellular localization of lipidated antibodies was demonstrated by confocal microscopy and by measuring cellular uptake of ¹²⁵I-labeled lipidated antibodies. Functionally, lipidated monoclonal antibody directed against the Tat protein from human immunodeficiency virus type 1 (HIV-1) inhibited viral replication of several HIV-1 isolates by approximately 85% as shown by increased viability of infected cells and decreased reverse transcriptase activity. The antibody in its native form had no such effect. These data show that lipidated antibodies can reach and functionally inhibit intracellular targets. Lipidation may help to facilitate the development of intracellular immunotherapy for AIDS.

PMID: 9117450 [PubMed - indexed for MEDLINE]



Show:



Sort

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

Dec 1 2003 07

Eukarion, Inc.
6F Alfred Circle
Bedford, MA 01730
Phone (781) 275-0424
Fax (781) 275-0752
www.eukarion.com

NEWS RELEASE

Contact:

Dr. Bernard Malfroy, CEO
781-275-0424

**HIV VIRAL REPLICATION IN LIVING CELLS BLOCKED
USING EUKARION ANTIBODY LIPIDATION
TECHNOLOGY**

(Bedford, MA, April 14, 1997) -- Eukarion, Inc. today announced that it has successfully blocked HIV-1 viral replication in living cells using a monoclonal antibody chemically modified to permit passage across cell membranes. A paper describing these results was published in the March issue of the Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.

"These findings are important for two reasons," said Bernard Malfroy, Ph.D., Eukarion's chief executive officer. "First, since HIV multiplies rapidly within cells, an approach to halting viral replication could contribute to the development of cell-specific AIDS immunotherapies." The Eukarion antibody targets the HIV-1 "Tat" protein that is required for HIV viral replication. In laboratory experiments using a human lymphocytic cell line, the modified (lipidated) anti-Tat antibody accumulated in HIV-1 infected cells. Once entering the infected cells, the lipidated anti-Tat antibody bound to the Tat protein and blocked its function, leading to suppressed viral replication and, concomitantly, to greatly improved cell survival. The lipidated anti-Tat antibody was found to be effective not only against a laboratory strain of HIV-1, but also against three strains of virus isolated from patients.

"Second and more broadly, we have demonstrated that Eukarion's lipidation technology can facilitate the delivery of antibodies to intracellular targets and that the antibodies retain their binding


specificity and activity," Dr. Malfroy said. "Most monoclonal antibody-based products in development today bind to sites on cell surfaces. With lipidation, we can now use antibodies to target disease-causing substances inside cells and significantly expand the use of monoclonal antibodies for the treatment of human diseases." Eukarion is also evaluating the use of its lipidation technology for other therapeutic applications, and for use with proteins other than antibodies.

The journal article was authored by William W. Cruikshank, Susan R. Doctrow, Melissa S. Falvo, Hardy Kornfeld, Karl Huffmann, Jay Raina and Dr. Malfroy. It represents a collaborative effort between researchers at Eukarion and the Boston University School of Medicine. Dr. Cruikshank, who is Associate Professor of Medicine, directed the principal studies in his laboratory at the B.U. Pulmonary Center.

In addition to its lipidation program, Eukarion has a separate effort underway to develop synthetic catalytic scavenger (SCS) compounds to target reactive oxygen intermediates (ROIs), toxic by-products of tissue stress. ROIs have been implicated in the irreversible damage that occurs in patients suffering from many chronic disorders including asthma, atherosclerosis, lupus, multiple sclerosis, neurodegenerative diseases of the central nervous system, ischemia-induced organ damage, allergy and adult respiratory distress syndrome. These seemingly diverse conditions appear to have ROI involvement as a common link, creating the potential for a small number of SCS compounds to address huge unmet medical needs.

In February 1997, Eukarion signed an agreement with Glaxo Wellcome plc, the world's largest research based pharmaceutical company, for a three year collaborative research and development program for the Eukarion SCS program. The agreement will provide Eukarion scientists with access to Glaxo Wellcome's substantial R&D and screening capabilities and will allow Eukarion to operate at break-even financial levels for the foreseeable future.

Eukarion, Inc., located in Bedford, MA, is a privately held company formed in 1991 to develop proprietary compounds directed against intracellular targets for the treatment of human disease. Eukarion's technologies are protected by issued and pending patent applications owned by the company.





| [home](#) | [r&d](#) | [press releases](#) | [info](#) | [publications](#) | [contact](#) |

contact : mail@eukarion.com